Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNA2 | P51530 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204593 | 0.80 | ALDH1A1 (0.56) | ADORA2ACYP1A2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL19220845 | 0.79 | DNA2 (0.72) | DNA2CASP6CTDSP1ADORA2ACYP1A2 | |
| SCHEMBL27660006 | 0.79 | HPGD (0.63) | CYP1A2CYP3A4ALDH1A1MAPK1HPGD | |
| SCHEMBL19220847 | 0.77 | DNA2 (0.62) | DNA2CASP6CTDSP1GUSBALDH1A1 | |
| SCHEMBL19220852 | 0.76 | DNA2 (0.71) | DNA2CASP6CTDSP1GUSBRAB9A | |
| SCHEMBL19220854 | 0.76 | CYP1A2 (0.53) | CYP1A2CYP3A4ALDH1A1MAPK1HPGD | |
| SCHEMBL19226218 | 0.76 | DNA2 (0.60) | DNA2CASP6CTDSP1GUSBALDH1A1 | |
| SCHEMBL4334739 | 0.74 | DNA2 (1.00) | DNA2CASP6CTDSP1CYP1A2GUSB | |
| SCHEMBL6537720 | 0.73 | DNA2 (0.78) | DNA2CASP6CTDSP1GUSBALDH1A1 | |
| SCHEMBL20153429 | 0.71 | DNA2 (0.62) | DNA2CASP6CTDSP1ADORA2AGUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2020-05-14 | — | — | US | disclosed |
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190092732-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2019-03-28 | — | — | US | disclosed |
| US-10173984-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134664-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2018-05-17 | — | — | US | disclosed |
| US-20180134664-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2018-05-17 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932310-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134664-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-10562856-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-20190092732-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-20200148645-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-20170226063-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-11198675-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-10173984-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.